A novel IkB kinase inhibitor attenuates ligature‐induced periodontal disease in mice

Backgrounds and Objectives IMD‐0354 is a novel I kappa‐B kinase (IKK) inhibitor, which regulates inflammation. The purpose of this study was to examine the effect of the reagent on bone loss for ligature‐induced periodontitis. Material and Methods We ligated around the upper right second molars of 8...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of periodontal research 2019-04, Vol.54 (2), p.164-173
Hauptverfasser: Kure, Keitetsu, Sato, Hiroki, Suzuki, Jun‐ichi, Itai, Akiko, Aoyama, Norio, Izumi, Yuichi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 173
container_issue 2
container_start_page 164
container_title Journal of periodontal research
container_volume 54
creator Kure, Keitetsu
Sato, Hiroki
Suzuki, Jun‐ichi
Itai, Akiko
Aoyama, Norio
Izumi, Yuichi
description Backgrounds and Objectives IMD‐0354 is a novel I kappa‐B kinase (IKK) inhibitor, which regulates inflammation. The purpose of this study was to examine the effect of the reagent on bone loss for ligature‐induced periodontitis. Material and Methods We ligated around the upper right second molars of 8‐week‐old C57BL/6J mice in the split‐mouth model. The test mice were injected intraperitoneally with IMD‐0354 before the placement of the ligature. The control mice were injected intraperitoneally with 0.5% carboxymethylcellulose (CMC) as vehicle before the placement of the ligature. To determine the optimum concentration of the reagent on ligature‐induced periodontitis in the mice, we examined the effect of three types of concentration, which were 1, 5, and 10 mg/kg of IMD‐0354, as a preliminary experiment. After we determined 10 mg/kg as the optimum concentration for the IMD group by micro‐CT analysis, both the IMD and CMC groups (n = 15 each in total, including all the analyses) were subdivided into two small groups, respectively, for further analyses: I group (unligated side of IMD group), IL group (ligated side of IMD group), C group (unligated side of CMC group) and CL group (ligated side of CMC group). The mice in the IMD and CMC groups were treated with each reagent daily and sacrificed 8 days after the ligation. For assessment of bone resorption, we performed micro‐CT and histological analyses. We also carried out real‐time PCR to investigate proinflammatory and bone metabolic markers. Results There were significant differences for linear bone loss and volumetric parameter in the test (IMD) group compared to the control (CMC) group 8 days after ligation. In terms of the mRNA expression level of gingival tissue, the level of RANKL was significantly suppressed in the IMD group compared to the CMC group. IMD‐0354 also tended to suppress the levels of interleukin‐1 beta, tumor necrosis factor‐alpha, and osteoprotegerin. For histological analysis, the relative numbers of TRAP‐positive multinucleated cells decreased significantly in the IMD group compared to the CMC group. Conclusion IMD‐0354 regulated bone resorption by ligature‐induced periodontitis, and it is suggested that the inhibition of IKK via down‐regulation of NF kappa‐B may provide periodontal patients with an effective approach to prevent or suppress the disease.
doi_str_mv 10.1111/jre.12615
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2117157534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2193987788</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5035-6a7be60dc91157e5265062e88dd460aece3aeaec7bc4292f388b0118ba686fae3</originalsourceid><addsrcrecordid>eNp1kM1Kw0AURgdRbK0ufAEZcKOL1PnJTCbLWqpWCoKo2zBJbnTaNKkzidKdj-Az-iSOproQvJuPC-ceLh9Ch5QMqZ-zuYUhZZKKLdSnkpCARFJsoz4hjAU8VGEP7Tk3J36XUbyLepywWHAm-uhhhKv6BUo8XZzjham0A2yqJ5OaprZYNw1UrW7A4dI86qa18PH2bqq8zSDHK7Cmzuuq0SXOjYPuFi9NBvtop9Clg4NNDtD9xeRufBXMbi6n49EsyAThIpA6SkGSPIspFREIJgWRDJTK81ASDRlwDT6iNAtZzAquVEooVamWShYa-ACddN6VrZ9bcE2yNC6DstQV1K1LGKWRNwseevT4DzqvW1v57zwV81hFkVKeOu2ozNbOWSiSlTVLbdcJJclX2YkvO_ku27NHG2ObLiH_JX_a9cBZB7yaEtb_m5Lr20mn_AT504lU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2193987788</pqid></control><display><type>article</type><title>A novel IkB kinase inhibitor attenuates ligature‐induced periodontal disease in mice</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kure, Keitetsu ; Sato, Hiroki ; Suzuki, Jun‐ichi ; Itai, Akiko ; Aoyama, Norio ; Izumi, Yuichi</creator><creatorcontrib>Kure, Keitetsu ; Sato, Hiroki ; Suzuki, Jun‐ichi ; Itai, Akiko ; Aoyama, Norio ; Izumi, Yuichi</creatorcontrib><description>Backgrounds and Objectives IMD‐0354 is a novel I kappa‐B kinase (IKK) inhibitor, which regulates inflammation. The purpose of this study was to examine the effect of the reagent on bone loss for ligature‐induced periodontitis. Material and Methods We ligated around the upper right second molars of 8‐week‐old C57BL/6J mice in the split‐mouth model. The test mice were injected intraperitoneally with IMD‐0354 before the placement of the ligature. The control mice were injected intraperitoneally with 0.5% carboxymethylcellulose (CMC) as vehicle before the placement of the ligature. To determine the optimum concentration of the reagent on ligature‐induced periodontitis in the mice, we examined the effect of three types of concentration, which were 1, 5, and 10 mg/kg of IMD‐0354, as a preliminary experiment. After we determined 10 mg/kg as the optimum concentration for the IMD group by micro‐CT analysis, both the IMD and CMC groups (n = 15 each in total, including all the analyses) were subdivided into two small groups, respectively, for further analyses: I group (unligated side of IMD group), IL group (ligated side of IMD group), C group (unligated side of CMC group) and CL group (ligated side of CMC group). The mice in the IMD and CMC groups were treated with each reagent daily and sacrificed 8 days after the ligation. For assessment of bone resorption, we performed micro‐CT and histological analyses. We also carried out real‐time PCR to investigate proinflammatory and bone metabolic markers. Results There were significant differences for linear bone loss and volumetric parameter in the test (IMD) group compared to the control (CMC) group 8 days after ligation. In terms of the mRNA expression level of gingival tissue, the level of RANKL was significantly suppressed in the IMD group compared to the CMC group. IMD‐0354 also tended to suppress the levels of interleukin‐1 beta, tumor necrosis factor‐alpha, and osteoprotegerin. For histological analysis, the relative numbers of TRAP‐positive multinucleated cells decreased significantly in the IMD group compared to the CMC group. Conclusion IMD‐0354 regulated bone resorption by ligature‐induced periodontitis, and it is suggested that the inhibition of IKK via down‐regulation of NF kappa‐B may provide periodontal patients with an effective approach to prevent or suppress the disease.</description><identifier>ISSN: 0022-3484</identifier><identifier>EISSN: 1600-0765</identifier><identifier>DOI: 10.1111/jre.12615</identifier><identifier>PMID: 30295325</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Alveolar Bone Loss - diagnostic imaging ; Alveolar Bone Loss - drug therapy ; Alveolar Bone Loss - etiology ; Alveolar Bone Loss - metabolism ; animal model ; Animals ; Benzamides - administration &amp; dosage ; Benzamides - pharmacology ; Bone loss ; Bone resorption ; Carboxymethylcellulose ; Dentistry ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Enzyme inhibitors ; Enzyme Inhibitors - administration &amp; dosage ; Enzyme Inhibitors - pharmacology ; Gene Expression ; Gingiva - metabolism ; Gum disease ; I-kappa B Kinase - antagonists &amp; inhibitors ; IKK inhibitor ; IKK protein ; Inflammation ; Injections, Intraperitoneal ; Interleukin-1beta - metabolism ; Ligation - adverse effects ; Mice, Inbred C57BL ; Molars ; Osteoprotegerin ; Osteoprotegerin - metabolism ; Periodontal diseases ; Periodontitis ; Periodontitis - diagnostic imaging ; Periodontitis - drug therapy ; Periodontitis - etiology ; Periodontitis - metabolism ; RANK Ligand - metabolism ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; Teeth ; TRANCE protein ; Tumor Necrosis Factor-alpha - metabolism ; X-Ray Microtomography</subject><ispartof>Journal of periodontal research, 2019-04, Vol.54 (2), p.164-173</ispartof><rights>2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd</rights><rights>2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2019 John Wiley &amp; Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5035-6a7be60dc91157e5265062e88dd460aece3aeaec7bc4292f388b0118ba686fae3</citedby><cites>FETCH-LOGICAL-c5035-6a7be60dc91157e5265062e88dd460aece3aeaec7bc4292f388b0118ba686fae3</cites><orcidid>0000-0003-2623-8255 ; 0000-0003-4716-8532 ; 0000-0001-7689-4440 ; 0000-0001-8959-579X ; 0000-0002-8498-4494</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjre.12615$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjre.12615$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30295325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kure, Keitetsu</creatorcontrib><creatorcontrib>Sato, Hiroki</creatorcontrib><creatorcontrib>Suzuki, Jun‐ichi</creatorcontrib><creatorcontrib>Itai, Akiko</creatorcontrib><creatorcontrib>Aoyama, Norio</creatorcontrib><creatorcontrib>Izumi, Yuichi</creatorcontrib><title>A novel IkB kinase inhibitor attenuates ligature‐induced periodontal disease in mice</title><title>Journal of periodontal research</title><addtitle>J Periodontal Res</addtitle><description>Backgrounds and Objectives IMD‐0354 is a novel I kappa‐B kinase (IKK) inhibitor, which regulates inflammation. The purpose of this study was to examine the effect of the reagent on bone loss for ligature‐induced periodontitis. Material and Methods We ligated around the upper right second molars of 8‐week‐old C57BL/6J mice in the split‐mouth model. The test mice were injected intraperitoneally with IMD‐0354 before the placement of the ligature. The control mice were injected intraperitoneally with 0.5% carboxymethylcellulose (CMC) as vehicle before the placement of the ligature. To determine the optimum concentration of the reagent on ligature‐induced periodontitis in the mice, we examined the effect of three types of concentration, which were 1, 5, and 10 mg/kg of IMD‐0354, as a preliminary experiment. After we determined 10 mg/kg as the optimum concentration for the IMD group by micro‐CT analysis, both the IMD and CMC groups (n = 15 each in total, including all the analyses) were subdivided into two small groups, respectively, for further analyses: I group (unligated side of IMD group), IL group (ligated side of IMD group), C group (unligated side of CMC group) and CL group (ligated side of CMC group). The mice in the IMD and CMC groups were treated with each reagent daily and sacrificed 8 days after the ligation. For assessment of bone resorption, we performed micro‐CT and histological analyses. We also carried out real‐time PCR to investigate proinflammatory and bone metabolic markers. Results There were significant differences for linear bone loss and volumetric parameter in the test (IMD) group compared to the control (CMC) group 8 days after ligation. In terms of the mRNA expression level of gingival tissue, the level of RANKL was significantly suppressed in the IMD group compared to the CMC group. IMD‐0354 also tended to suppress the levels of interleukin‐1 beta, tumor necrosis factor‐alpha, and osteoprotegerin. For histological analysis, the relative numbers of TRAP‐positive multinucleated cells decreased significantly in the IMD group compared to the CMC group. Conclusion IMD‐0354 regulated bone resorption by ligature‐induced periodontitis, and it is suggested that the inhibition of IKK via down‐regulation of NF kappa‐B may provide periodontal patients with an effective approach to prevent or suppress the disease.</description><subject>Alveolar Bone Loss - diagnostic imaging</subject><subject>Alveolar Bone Loss - drug therapy</subject><subject>Alveolar Bone Loss - etiology</subject><subject>Alveolar Bone Loss - metabolism</subject><subject>animal model</subject><subject>Animals</subject><subject>Benzamides - administration &amp; dosage</subject><subject>Benzamides - pharmacology</subject><subject>Bone loss</subject><subject>Bone resorption</subject><subject>Carboxymethylcellulose</subject><subject>Dentistry</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Enzyme inhibitors</subject><subject>Enzyme Inhibitors - administration &amp; dosage</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Gene Expression</subject><subject>Gingiva - metabolism</subject><subject>Gum disease</subject><subject>I-kappa B Kinase - antagonists &amp; inhibitors</subject><subject>IKK inhibitor</subject><subject>IKK protein</subject><subject>Inflammation</subject><subject>Injections, Intraperitoneal</subject><subject>Interleukin-1beta - metabolism</subject><subject>Ligation - adverse effects</subject><subject>Mice, Inbred C57BL</subject><subject>Molars</subject><subject>Osteoprotegerin</subject><subject>Osteoprotegerin - metabolism</subject><subject>Periodontal diseases</subject><subject>Periodontitis</subject><subject>Periodontitis - diagnostic imaging</subject><subject>Periodontitis - drug therapy</subject><subject>Periodontitis - etiology</subject><subject>Periodontitis - metabolism</subject><subject>RANK Ligand - metabolism</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Teeth</subject><subject>TRANCE protein</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>X-Ray Microtomography</subject><issn>0022-3484</issn><issn>1600-0765</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1Kw0AURgdRbK0ufAEZcKOL1PnJTCbLWqpWCoKo2zBJbnTaNKkzidKdj-Az-iSOproQvJuPC-ceLh9Ch5QMqZ-zuYUhZZKKLdSnkpCARFJsoz4hjAU8VGEP7Tk3J36XUbyLepywWHAm-uhhhKv6BUo8XZzjham0A2yqJ5OaprZYNw1UrW7A4dI86qa18PH2bqq8zSDHK7Cmzuuq0SXOjYPuFi9NBvtop9Clg4NNDtD9xeRufBXMbi6n49EsyAThIpA6SkGSPIspFREIJgWRDJTK81ASDRlwDT6iNAtZzAquVEooVamWShYa-ACddN6VrZ9bcE2yNC6DstQV1K1LGKWRNwseevT4DzqvW1v57zwV81hFkVKeOu2ozNbOWSiSlTVLbdcJJclX2YkvO_ku27NHG2ObLiH_JX_a9cBZB7yaEtb_m5Lr20mn_AT504lU</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Kure, Keitetsu</creator><creator>Sato, Hiroki</creator><creator>Suzuki, Jun‐ichi</creator><creator>Itai, Akiko</creator><creator>Aoyama, Norio</creator><creator>Izumi, Yuichi</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2623-8255</orcidid><orcidid>https://orcid.org/0000-0003-4716-8532</orcidid><orcidid>https://orcid.org/0000-0001-7689-4440</orcidid><orcidid>https://orcid.org/0000-0001-8959-579X</orcidid><orcidid>https://orcid.org/0000-0002-8498-4494</orcidid></search><sort><creationdate>201904</creationdate><title>A novel IkB kinase inhibitor attenuates ligature‐induced periodontal disease in mice</title><author>Kure, Keitetsu ; Sato, Hiroki ; Suzuki, Jun‐ichi ; Itai, Akiko ; Aoyama, Norio ; Izumi, Yuichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5035-6a7be60dc91157e5265062e88dd460aece3aeaec7bc4292f388b0118ba686fae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Alveolar Bone Loss - diagnostic imaging</topic><topic>Alveolar Bone Loss - drug therapy</topic><topic>Alveolar Bone Loss - etiology</topic><topic>Alveolar Bone Loss - metabolism</topic><topic>animal model</topic><topic>Animals</topic><topic>Benzamides - administration &amp; dosage</topic><topic>Benzamides - pharmacology</topic><topic>Bone loss</topic><topic>Bone resorption</topic><topic>Carboxymethylcellulose</topic><topic>Dentistry</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Enzyme inhibitors</topic><topic>Enzyme Inhibitors - administration &amp; dosage</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Gene Expression</topic><topic>Gingiva - metabolism</topic><topic>Gum disease</topic><topic>I-kappa B Kinase - antagonists &amp; inhibitors</topic><topic>IKK inhibitor</topic><topic>IKK protein</topic><topic>Inflammation</topic><topic>Injections, Intraperitoneal</topic><topic>Interleukin-1beta - metabolism</topic><topic>Ligation - adverse effects</topic><topic>Mice, Inbred C57BL</topic><topic>Molars</topic><topic>Osteoprotegerin</topic><topic>Osteoprotegerin - metabolism</topic><topic>Periodontal diseases</topic><topic>Periodontitis</topic><topic>Periodontitis - diagnostic imaging</topic><topic>Periodontitis - drug therapy</topic><topic>Periodontitis - etiology</topic><topic>Periodontitis - metabolism</topic><topic>RANK Ligand - metabolism</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Teeth</topic><topic>TRANCE protein</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>X-Ray Microtomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kure, Keitetsu</creatorcontrib><creatorcontrib>Sato, Hiroki</creatorcontrib><creatorcontrib>Suzuki, Jun‐ichi</creatorcontrib><creatorcontrib>Itai, Akiko</creatorcontrib><creatorcontrib>Aoyama, Norio</creatorcontrib><creatorcontrib>Izumi, Yuichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of periodontal research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kure, Keitetsu</au><au>Sato, Hiroki</au><au>Suzuki, Jun‐ichi</au><au>Itai, Akiko</au><au>Aoyama, Norio</au><au>Izumi, Yuichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A novel IkB kinase inhibitor attenuates ligature‐induced periodontal disease in mice</atitle><jtitle>Journal of periodontal research</jtitle><addtitle>J Periodontal Res</addtitle><date>2019-04</date><risdate>2019</risdate><volume>54</volume><issue>2</issue><spage>164</spage><epage>173</epage><pages>164-173</pages><issn>0022-3484</issn><eissn>1600-0765</eissn><abstract>Backgrounds and Objectives IMD‐0354 is a novel I kappa‐B kinase (IKK) inhibitor, which regulates inflammation. The purpose of this study was to examine the effect of the reagent on bone loss for ligature‐induced periodontitis. Material and Methods We ligated around the upper right second molars of 8‐week‐old C57BL/6J mice in the split‐mouth model. The test mice were injected intraperitoneally with IMD‐0354 before the placement of the ligature. The control mice were injected intraperitoneally with 0.5% carboxymethylcellulose (CMC) as vehicle before the placement of the ligature. To determine the optimum concentration of the reagent on ligature‐induced periodontitis in the mice, we examined the effect of three types of concentration, which were 1, 5, and 10 mg/kg of IMD‐0354, as a preliminary experiment. After we determined 10 mg/kg as the optimum concentration for the IMD group by micro‐CT analysis, both the IMD and CMC groups (n = 15 each in total, including all the analyses) were subdivided into two small groups, respectively, for further analyses: I group (unligated side of IMD group), IL group (ligated side of IMD group), C group (unligated side of CMC group) and CL group (ligated side of CMC group). The mice in the IMD and CMC groups were treated with each reagent daily and sacrificed 8 days after the ligation. For assessment of bone resorption, we performed micro‐CT and histological analyses. We also carried out real‐time PCR to investigate proinflammatory and bone metabolic markers. Results There were significant differences for linear bone loss and volumetric parameter in the test (IMD) group compared to the control (CMC) group 8 days after ligation. In terms of the mRNA expression level of gingival tissue, the level of RANKL was significantly suppressed in the IMD group compared to the CMC group. IMD‐0354 also tended to suppress the levels of interleukin‐1 beta, tumor necrosis factor‐alpha, and osteoprotegerin. For histological analysis, the relative numbers of TRAP‐positive multinucleated cells decreased significantly in the IMD group compared to the CMC group. Conclusion IMD‐0354 regulated bone resorption by ligature‐induced periodontitis, and it is suggested that the inhibition of IKK via down‐regulation of NF kappa‐B may provide periodontal patients with an effective approach to prevent or suppress the disease.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30295325</pmid><doi>10.1111/jre.12615</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2623-8255</orcidid><orcidid>https://orcid.org/0000-0003-4716-8532</orcidid><orcidid>https://orcid.org/0000-0001-7689-4440</orcidid><orcidid>https://orcid.org/0000-0001-8959-579X</orcidid><orcidid>https://orcid.org/0000-0002-8498-4494</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-3484
ispartof Journal of periodontal research, 2019-04, Vol.54 (2), p.164-173
issn 0022-3484
1600-0765
language eng
recordid cdi_proquest_miscellaneous_2117157534
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Alveolar Bone Loss - diagnostic imaging
Alveolar Bone Loss - drug therapy
Alveolar Bone Loss - etiology
Alveolar Bone Loss - metabolism
animal model
Animals
Benzamides - administration & dosage
Benzamides - pharmacology
Bone loss
Bone resorption
Carboxymethylcellulose
Dentistry
Disease Models, Animal
Dose-Response Relationship, Drug
Enzyme inhibitors
Enzyme Inhibitors - administration & dosage
Enzyme Inhibitors - pharmacology
Gene Expression
Gingiva - metabolism
Gum disease
I-kappa B Kinase - antagonists & inhibitors
IKK inhibitor
IKK protein
Inflammation
Injections, Intraperitoneal
Interleukin-1beta - metabolism
Ligation - adverse effects
Mice, Inbred C57BL
Molars
Osteoprotegerin
Osteoprotegerin - metabolism
Periodontal diseases
Periodontitis
Periodontitis - diagnostic imaging
Periodontitis - drug therapy
Periodontitis - etiology
Periodontitis - metabolism
RANK Ligand - metabolism
RNA, Messenger - genetics
RNA, Messenger - metabolism
Teeth
TRANCE protein
Tumor Necrosis Factor-alpha - metabolism
X-Ray Microtomography
title A novel IkB kinase inhibitor attenuates ligature‐induced periodontal disease in mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T21%3A30%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20novel%20IkB%20kinase%20inhibitor%20attenuates%20ligature%E2%80%90induced%20periodontal%20disease%20in%20mice&rft.jtitle=Journal%20of%20periodontal%20research&rft.au=Kure,%20Keitetsu&rft.date=2019-04&rft.volume=54&rft.issue=2&rft.spage=164&rft.epage=173&rft.pages=164-173&rft.issn=0022-3484&rft.eissn=1600-0765&rft_id=info:doi/10.1111/jre.12615&rft_dat=%3Cproquest_cross%3E2193987788%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2193987788&rft_id=info:pmid/30295325&rfr_iscdi=true